Multivariate analysis for leukemia-free survival (LFS) in patients without any acute or chronic GVHD who underwent a URD or HLA-identical sibling transplantation for AML, ALL, and CML
| Factors . | Relative risk . | 95% CI . | P . |
|---|---|---|---|
| AML*: URD vs sib | 2.17 | 1.67-2.80 | < .001 |
| ALL†: URD vs sib | 1.69 | 1.10-2.62 | .017 |
| CML‡: URD vs sib | 1.48 | 1.04-2.12 | .03 |
| Factors . | Relative risk . | 95% CI . | P . |
|---|---|---|---|
| AML*: URD vs sib | 2.17 | 1.67-2.80 | < .001 |
| ALL†: URD vs sib | 1.69 | 1.10-2.62 | .017 |
| CML‡: URD vs sib | 1.48 | 1.04-2.12 | .03 |
In patients without acute or chronic GVHD, LFS is decreased in URD compared with HLA-identical sibling transplantations for AML, ALL, and CML
URD indicates unrelated donor; Sib, HLA-identical sibling; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia, GVHD, graft-versus-host disease; CI, confidence interval; and CR1, first complete remission. RR for reference group (sib) is 1.0.
Model also adjusted for duration of CR1 and cytogenetics, and stratified by disease stage, Karnofsky score, and graft type.
Model also adjusted for patient age at transplant and stratified by disease stage, Karnofsky score, and graft type.
Model also adjusted for patient age and stratified by disease stage, Karnofsky score, and graft type.